Table 2.
Complications as reported by study including overall complication rate, specific adverse events, and buried glands. Note that methods for collecting information on adverse events varied widely between studies
| Study | Total complications/number of patients | Pain | Dysphagia | Fever | Bleeding | Perforation | Stricture | Photosensitivity | Abnormal LFT | Nausea/vomiting | Buried glands |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MPEC | |||||||||||
| Sampliner et al. [25] | 25/58 MPEC | 33% | n/a | 3% | 2% | 0 | 2% | n/a | n/a | 1% | 5% |
| APC | |||||||||||
| Bright et al. [29] | 2/20 APC | n/a | n/a | n/a | n/a | n/a | 10% | n/a | n/a | n/a | 5% pre-treatment 10% surveillance 10% APC |
| PDT | |||||||||||
| Ackroyd et al. [32] | 19/18 PDT 0/18 placebo |
100% PDT | n/a | n/a | n/a | n/a | n/a | 6% | n/a | n/a | 0 |
| Overholt et al. [10, 33] | 132/133 PDT 51/69 PPI |
20% PDT | 19% PDT | 20% PDT | 0 | 1% during dilation | 36% PDT 0 PPI |
69% PDT (n=92) one with permanent scars |
n/a | 32% PDT | n/a |
| APC vs MPEC | |||||||||||
| Dulai et al. [27] | 1/26 APC 0/26 MPEC |
4% APC | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 0 when serial sections evaluated |
| Sharma et al. [28] | 17/19 APC 20/16 MPEC |
21% APC 38% MPEC |
11% APC 31% MPEC |
5% APC | 0 | 0 | 5% APC | n/a | n/a | n/a | n/a |
| PDT vs APC | |||||||||||
| Hage et al. [35] | 60/26 PDT 14/14 APC |
92% PDT 86% APC |
n/a | 31% PDT 14% APC |
n/a | n/a | n/a | n/a | 77% PDT 0 APC |
27% PDT 0 APC |
78% APC |
| Kelty et al. [36] | 23/34 PDT 67/34 APC |
3% PDT 100% APC |
94% APC | n/a | n/a | 0 | 3% APC | 15% PDT | 12% PDT | 32% PDT | 24% PDT 21% APC |
| RFA | |||||||||||
| Roorda et al. [40] | 6/13 RFA | 23% | 23% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 0 |
| Sharma et al. [37], Fleischer et al. [38, 39] | 12/32 safety RFA 24/70 efficacy RFA |
12% 13% |
n/a | 9% 3% |
1% | n/a | n/a | n/a | n/a | 3% 11% |
0 |
| Gondrie et al. [41] | 12/11 RFA | 73% | 27% | 9% | 0 | 0 | 0 | n/a | n/a | n/a | 0 |
| Gondrie et al. [42] | 1/12 RFA | n/a | n/a | n/a | n/a | n/a | 8% | n/a | n/a | n/a | 0 |
| Sharma et al. [43] | 1/10 RFA | n/a | n/a | n/a | 10% | n/a | 0 | n/a | n/a | n/a | 0 |
| Hernandez et al. [44] | n/a RFA | Yes, but number not provided | n/a | n/a | n/a | 0 | 0 | n/a | n/a | n/a | 10% |
| Ganz et al. 2008 [46] | 1/142 RFA | n/a | n/a | n/a | n/a | n/a | 1% | n/a | n/a | n/a | 0 |
| Sharma et al. [45] | 2/63 RFA | n/a | n/a | n/a | 1% | n/a | 1% | n/a | n/a | n/a | 0 |
| Eldaif et al. [56] | 0/27 RFA | n/a | 0 | n/a | n/a | n/a | 0 | n/a | n/a | n/a | 0 |
| Shaheen et al. [9] | 8/84 RFA | 2% RFA | n/a | n/a | n/a | n/a | 6% RFA | n/a | n/a | 1% | 5% RFA 40% sham control |
| Velanovich et al. [48] | 4/66 RFA | n/a | n/a | n/a | n/a | n/a | 7% | n/a | n/a | n/a | n/a |
| Pouw et al. [47] | 9/24 RFA | n/a | 4% | n/a | 4% | 4% | 4% | n/a | n/a | n/a | 0 |
| Vassiliou et al. [49] | 5/59 RFA | n/a | n/a | n/a | 2% | n/a | 3% | n/a | n/a | 3% | 0 |
| Cryotherapy | |||||||||||
| Johnston et al. [50] | 4/11 cryotherapy | 18% | 18% | n/a | 0 | 0 | 0 | n/a | n/a | n/a | 18% |
| Dumot et al. [51] | 12/31 cryotherapy | 23% | 0 | n/a | n/a | 3% | 10% | n/a | n/a | 0 | n/a |
| Shaheen et al. [57] | 6/98 cryotherapy | 2% | n/a | n/a | 1% | n/a | 3% | n/a | n/a | n/a | 3% |
| EMR | |||||||||||
| Chennat et al. [31] | 20/49 EMR | 2% | n/a | n/a | 0 | 0 | 37% | n/a | n/a | n/a | 3% |
| Pouw et al. [54] | 91/169 EMR | n/a | n/a | n/a | 2% | 2% | 50% | n/a | n/a | n/a | 3% |
APC—argon plasma coagulation; EMR—endoscopic mucosal resection; LFT—liver function tests; MPEC—multipolar electrocoagulation; n/a—not available; PDT—photodynamic therapy; RFA—radiofrequency ablation.